Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 2.80
NSPR's Cash-to-Debt is ranked higher than
51% of the 325 Companies
in the Global Medical Devices industry.

( Industry Median: 2.55 vs. NSPR: 2.80 )
Ranked among companies with meaningful Cash-to-Debt only.
NSPR' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.62  Med: 5026.6 Max: No Debt
Current: 2.8
Equity-to-Asset 0.43
NSPR's Equity-to-Asset is ranked lower than
76% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 0.63 vs. NSPR: 0.43 )
Ranked among companies with meaningful Equity-to-Asset only.
NSPR' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.52  Med: 0.43 Max: 0.78
Current: 0.43
-0.52
0.78
Piotroski F-Score: 5
Altman Z-Score: -20.90
Beneish M-Score: -4.76
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -403.75
NSPR's Operating Margin % is ranked lower than
89% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 2.62 vs. NSPR: -403.75 )
Ranked among companies with meaningful Operating Margin % only.
NSPR' s Operating Margin % Range Over the Past 10 Years
Min: -840.95  Med: -365.91 Max: -228.66
Current: -403.75
-840.95
-228.66
Net Margin % -446.67
NSPR's Net Margin % is ranked lower than
89% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 1.55 vs. NSPR: -446.67 )
Ranked among companies with meaningful Net Margin % only.
NSPR' s Net Margin % Range Over the Past 10 Years
Min: -890.53  Med: -523.57 Max: -244.25
Current: -446.67
-890.53
-244.25
ROA % -121.47
NSPR's ROA % is ranked lower than
91% of the 327 Companies
in the Global Medical Devices industry.

( Industry Median: 0.06 vs. NSPR: -121.47 )
Ranked among companies with meaningful ROA % only.
NSPR' s ROA % Range Over the Past 10 Years
Min: -436.36  Med: -230.92 Max: -80
Current: -121.47
-436.36
-80
ROC (Joel Greenblatt) % -1861.89
NSPR's ROC (Joel Greenblatt) % is ranked lower than
88% of the 323 Companies
in the Global Medical Devices industry.

( Industry Median: 4.26 vs. NSPR: -1861.89 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NSPR' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -8439.86  Med: -2238.93 Max: -1484.91
Current: -1861.89
-8439.86
-1484.91
3-Year Revenue Growth Rate -71.60
NSPR's 3-Year Revenue Growth Rate is ranked lower than
96% of the 237 Companies
in the Global Medical Devices industry.

( Industry Median: 4.40 vs. NSPR: -71.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NSPR' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -71.6 Max: -41.4
Current: -71.6
3-Year EBITDA Growth Rate -73.80
NSPR's 3-Year EBITDA Growth Rate is ranked lower than
98% of the 208 Companies
in the Global Medical Devices industry.

( Industry Median: 5.10 vs. NSPR: -73.80 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NSPR' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -73.8  Med: -9 Max: 685.3
Current: -73.8
-73.8
685.3
3-Year EPS without NRI Growth Rate -74.30
NSPR's 3-Year EPS without NRI Growth Rate is ranked lower than
96% of the 203 Companies
in the Global Medical Devices industry.

( Industry Median: 1.40 vs. NSPR: -74.30 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NSPR' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -40.1 Max: 370.7
Current: -74.3
0
370.7
GuruFocus has detected 2 Warning Signs with InspireMD Inc $NSPR.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NSPR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

NSPR Guru Trades in

NSPR Guru Trades in

Q3 2016

NSPR Guru Trades in Q3 2016

Jim Simons 1,923,051 sh (New)
» More
Q4 2016

NSPR Guru Trades in Q4 2016

Jim Simons 109,742 sh (+42.67%)
» More
» Details

Insider Trades

Latest Guru Trades with NSPR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 339112    SIC: 3841
Compare:OTCPK:IGNG, OTCPK:AIRW, OTCPK:MPHMF, OTCPK:VYCO, OTCPK:PETV, NAS:PHMD, NAS:MDGS, NAS:SSH, OTCPK:ACAR, OTCPK:EQUR, OTCPK:ACXA, NAS:AHPI, OTCPK:ESMC, OTCPK:BIAD, OTCPK:PYNGF, OTCBB:GTHP, OTCPK:NUMD, AMEX:XTNT, OTCPK:PBIO, NAS:EVAR » details
Traded in other countries:II2N.Germany,
Headquarter Location:Israel
InspireMD Inc is a medical device company. The Company is engaged in the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease.

InspireMD Inc was organized in the State of Delaware on February 29, 2008 as Saguaro Resources, Inc. On March 28, 2011, it effectuated a 1-for-3 forward stock split and changed its name from Saguaro Resources, Inc. to InspireMD, Inc. It is an medical device company focusing on the development and commercialization of its proprietary stent platform technology, MGuard. MGuard provides embolic protection in stenting procedures by placing a micron mesh sleeve over a stent. The Company's initial products are marketed for use mainly in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). According to the TYPHOON STEMI trial and the SOS SVG Trial of patients with acute myocardial infarction and saphenous vein graft coronary interventions, 7.5% to 44% experience adverse cardiac events, including cardiac death, heart attack, and restenting of the artery. When performing stenting procedures in patients with acute coronary symptoms, interventional cardiologists face a difficult dilemma in choosing between bare-metal stents, which have a high rate of restenosis (formation of new blockages), and drug-eluting (drug-coated) stents, which have a high rate of late thrombosis (formation of clots months or years after implantation), require administration of anti-platelet drugs for at least one year post procedure, are more costly than bare-metal stents and have additional side effects. It intends to use its MGuard technology in a broad range of coronary related situations in which complex lesions are required and make it an industry standard for treatment of acute coronary syndromes. It also intends to apply its technology to develop additional products used for other vascular procedures, specifically carotid (the arteries that supply blood to the brain) and peripheral (other arteries) procedures. The Company markets its products through distributers in international markets, mainly in Europe and Latin America.

Top Ranked Articles about InspireMD Inc

InspireMD Announces Pricing of Public Offering of Approximately $14.6 Million

BOSTON, MA--(Marketwired - Jun 30, 2016) - InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, today announced the pricing of a "best efforts" public offering of approximately 442,424 shares of Series B Convertible Preferred Stock and accompanying warrants to purchase up to approximately 44,242,424 million shares of common stock. Each share of Series B Convertible Preferred Stock is convertible into 100 shares of common stock at a conversion price equal to $0.33 per share, and the holders of Series B Convertible Preferred Stock will be entitled to receive cumulative dividends at the rate per share of 15% per annum of the stated value for five years. The warrants shall be exercisable immediately and have a term of exercise of five years from the date of issuance and have an exercise price of $0.20 per share of common stock. The Company expects to receive gross proceeds of approximately $14.6 million from the offering, before deducting placement agent fees and estimated offering expenses payable by the Company, assuming completion of the maximum offering. The offering is expected to close on or about July 7, 2016, subject to customary closing conditions. The Company intends to use the net proceeds from the offering to conduct sales activities related to CGuard™ EPS™, MGuard Prime™ EPS and develop its pipeline of new products and for general corporate purposes. Dawson James Securities, Inc. is acting as the sole placement agent.  The securities intended to be sold in the offering described above are being offered pursuant to a registration statement on Form S-1 which was filed with the Securities and Exchange Commission ("SEC") and was declared effective on June 30, 2016. A final prospectus supplement relating to the offering will be filed with the SEC by July 1, 2016. Copies of the prospectus relating to the offering may be obtained from Dawson James Securities, Inc., Attention: Prospectus Department, 1 North Federal Highway, 5th Floor, Boca Raton, FL 33432, [email protected] or toll free at 866.928.0928. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About InspireMD, Inc. InspireMD seeks to utilize its proprietary MicroNet™ technology to make its products the industry standard for embolic protection and to provide a superior solution to the key clinical issues of current stenting in patients with a high risk of distal embolization, no reflow and major adverse cardiac events. InspireMD intends to pursue applications of this MicroNet™ technology in coronary, carotid (CGuard™), neurovascular, and peripheral artery procedures. InspireMD's common stock is quoted on the NYSE MKT under the ticker symbol NSPR. Forward-looking Statements This press release contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.


Investor Contacts:

InspireMD, Inc.

Craig Shore

Chief Financial Officer

Phone: 1-888-776-6804 FREE

Email: [email protected]


PCG Advisory

Vivian Cervantes

Investor Relations

Phone: (212) 554-5482





Read more...
CORRECTION - InspireMD Announces Pricing of Public Offering of Approximately $14.6 Million

BOSTON, MA--(Marketwired - Jun 30, 2016) - In the news release, "InspireMD Announces Pricing of Public Offering of Approximately $14.6 Million," issued earlier today by InspireMD, Inc. (NYSE MKT: NSPR), we are advised by the company that in the first sentence of the first paragraph, it should read "44,242,424 shares" rather than "44,242,424 million shares" as originally issued. Complete corrected text follows. InspireMD Announces Pricing of Public Offering of Approximately $14.6 Million BOSTON, MA -- June 30, 2016 -- InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, today announced the pricing of a "best efforts" public offering of approximately 442,424 shares of Series B Convertible Preferred Stock and accompanying warrants to purchase up to approximately 44,242,424 shares of common stock. Each share of Series B Convertible Preferred Stock is convertible into 100 shares of common stock at a conversion price equal to $0.33 per share, and the holders of Series B Convertible Preferred Stock will be entitled to receive cumulative dividends at the rate per share of 15% per annum of the stated value for five years. The warrants shall be exercisable immediately and have a term of exercise of five years from the date of issuance and have an exercise price of $0.20 per share of common stock. The Company expects to receive gross proceeds of approximately $14.6 million from the offering, before deducting placement agent fees and estimated offering expenses payable by the Company, assuming completion of the maximum offering. The offering is expected to close on or about July 7, 2016, subject to customary closing conditions. The Company intends to use the net proceeds from the offering to conduct sales activities related to CGuard™ EPS™, MGuard Prime™ EPS and develop its pipeline of new products and for general corporate purposes. Dawson James Securities, Inc. is acting as the sole placement agent.  The securities intended to be sold in the offering described above are being offered pursuant to a registration statement on Form S-1 which was filed with the Securities and Exchange Commission ("SEC") and was declared effective on June 30, 2016. A final prospectus supplement relating to the offering will be filed with the SEC by July 1, 2016. Copies of the prospectus relating to the offering may be obtained from Dawson James Securities, Inc., Attention: Prospectus Department, 1 North Federal Highway, 5th Floor, Boca Raton, FL 33432, [email protected] or toll free at 866.928.0928. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About InspireMD, Inc. InspireMD seeks to utilize its proprietary MicroNet™ technology to make its products the industry standard for embolic protection and to provide a superior solution to the key clinical issues of current stenting in patients with a high risk of distal embolization, no reflow and major adverse cardiac events. InspireMD intends to pursue applications of this MicroNet™ technology in coronary, carotid (CGuard™), neurovascular, and peripheral artery procedures. InspireMD's common stock is quoted on the NYSE MKT under the ticker symbol NSPR. Forward-looking Statements This press release contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.


Investor Contacts:

InspireMD, Inc.

Craig Shore

Chief Financial Officer

Phone: 1-888-776-6804 FREE

Email: [email protected]



PCG Advisory

Vivian Cervantes

Investor Relations

Phone: (212) 554-5482





Read more...
InspireMD Announces Amendment to Loan & Security Agreement With Hercules Capital

Principal Payments Deferred, Assisting Cash Management Programs

BOSTON, MA--(Marketwired - Jun 14, 2016) - InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, today announced that it has completed a restructuring of its existing debt.  The Company restructured its term loan with lenders and Hercules Capital ("Hercules" or "Lenders"), which has an outstanding balance of approximately $3.6 million, effective immediately. Under the terms of the No. 3 Amendment to Loan and Security Agreement and subject to the satisfaction of certain interest only period extension conditions, all parties have agreed to a deferral of payment of principal for a four month period beginning May 1st, 2016. The Company will be subject to certain additional covenants, and will pay a financing fee to the Lenders, that are in line with transactions of this type. About InspireMD, Inc. InspireMD seeks to utilize its proprietary MicroNet™ technology to make its products the industry standard for embolic protection and to provide a superior solution to the key clinical issues of current stenting in patients with a high risk of distal embolization, no reflow and major adverse cardiac events. InspireMD intends to pursue applications of this MicroNet™ technology in coronary, carotid (CGuard™), neurovascular, and peripheral artery procedures. InspireMD's common stock is quoted on the NYSE MKT under the ticker symbol NSPR. Forward-looking Statements This press release contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.


Investor Contacts:

InspireMD, Inc.

Craig Shore

Chief Financial Officer

Phone (Skype): 1-888-776-6804 FREE

Email: [email protected]


PCG Advisory

Vivian Cervantes

Investor Relations

Phone: (212) 554-5482





Read more...
InspireMD Names Dr. James Barry as President and CEO

Medical Device Veteran Brings Broad Industry Experience in Pioneering Technologies

BOSTON, MA--(Marketwired - Jun 7, 2016) - InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, today announced the appointment of James Barry, Ph.D. as President and CEO effective immediately. Prior to this appointment, Dr. Barry served as InspireMD's Chief Operating Officer since July 2014 and has been a member of the Company's Board of Directors since January 2012. He replaces Alan Milinazzo, who previously announced his decision to step down as Director, President and CEO in January 2016. Mr. Milinazzo will continue to serve as an advisor to the Company. Dr. Barry brings more than two decades of experience in the medical device industry. For more than 18 years, he held senior roles at Boston Scientific Corporation. Dr. Barry initiated and oversaw the development of Boston Scientific's Taxus™ stent which quickly became the number one selling drug eluting stent worldwide. He also oversaw the development of the technology that is employed in the Synergy™ Everolimus-Eluting Stent System. Sol J. Barer, Ph.D., Chairman of InspireMD, commented, "We are extremely pleased to name Dr. Barry as President and CEO. Jim brings an invaluable set of capabilities, relationships, and experience in line with our efforts to pioneer and commercialize new device technologies that leverage our proprietary MicroNet™ platform. Jim is well-versed in the Company, as a Board Member and in his previous role as the Company's Chief Operating Officer, where he led initiatives to realign the organization around corporate strategic objectives, such as the transition into the carotid and neuro interventional markets, and also to design, develop, obtain regulatory clearances, and begin commercial activities for CGuard™ EPS." Dr. Barry commented, "I am excited to take on the challenge of driving broad clinical and commercial acceptance of our CGuard™ technology. We have a growing body of clinical evidence that supports the therapeutic benefits of CGuard™, which has been well received so far by the clinical community. We are now well focused on bringing that innovative success to gaining commercial traction. I look forward to ongoing, targeted initiatives with our distributor partners, including Penumbra, to develop broad based markets where our products are of routine clinical use. Finally, I am delighted to continue to serve with and further build around the focused, dedicated and talented team of InspireMD." In addition to serving as a Board Member of InspireMD, Dr. Barry serves on a number of Advisory Boards including the College of Biomedical Engineering at Yale University, the College of Sciences at University of Massachusetts-Lowell, and the Massachusetts Life Science Center. Dr. Barry holds a Bachelor's Degree in Chemistry from St. Anselm College and a Ph.D. in Biochemistry from the University of Massachusetts-Lowell. About CGuard™ EPS The proprietary CGuard™ Embolic Prevention System (EPS) uses the same MicroNet™ technology featured on the MGuard™ and MGuard Prime™ coronary Embolic Protection Systems. The CGuard™ EPS is designed to prevent peri-procedural and late embolization by trapping potential emboli against the arterial wall while maintaining excellent perfusion to the external carotid artery and branch vessels. MicroNet™ is a bio-stable mesh woven from a single strand of 20 micron Polyethylene Terephthalate (PET). CGuard™ EPS is CE Marked and not approved for sale in the U.S. by the U.S. Food and Drug Administration at this time. About InspireMD, Inc. InspireMD seeks to utilize its proprietary MicroNet™ technology to make its products the industry standard for embolic protection and to provide a superior solution to the key clinical issues of current stenting in patients with a high risk of distal embolization, no reflow and major adverse cardiac events. InspireMD intends to pursue applications of this MicroNet™ technology in coronary, carotid (CGuard™), neurovascular, and peripheral artery procedures. InspireMD's common stock is quoted on the NYSE MKT under the ticker symbol NSPR. Forward-looking Statements This press release contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.


Investor Contacts:

InspireMD, Inc.

Craig Shore

Chief Financial Officer

Phone: 1-888-776-6804 FREE

Email: [email protected]


PCG Advisory

Vivian Cervantes

Investor Relations

Phone: (212) 554-5482





Read more...
InspireMD Announces Late-Breaking Trial Presentation on CGuard(TM) Embolic Prevention System at EuroPCR 2016 Conference

BOSTON, MA--(Marketwired - May 5, 2016) - InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, today announced that CGuard™ EPS will be featured at the Late-Breaking Trial presentation at the upcoming EuroPCR conference from May 17-20, 2016 in Paris, France. A leading course in interventional cardiovascular medicine, EuroPCR hosts over 120 companies from the industry, including device and equipment manufacturers. The event allows attendees to discover new products and R&D projects, as well as interact with practitioners and industry partners to drive continued development and innovation in the interventional cardiovascular field. InspireMD's CGuard™ system will be featured in a session comprising selected EuroPCR 2016 Late-Breaking Trial submissions with emphasis on pioneering studies that are changing clinical practice: Tuesday, May 17th

12:26 - 12:34, Room Maillot Renal Denervation, Carotid Stenting

Prospective evaluation of all-comer percutaneous carotid revascularisation In symptomatic and increased-risk asymptomatic carotid artery stenosis using the Micronet-covered embolic prevention stent system in 101 consecutive patients: PARADIGM-101, Piotr Musialek, Poland PARADIGM-101 or PARADIGM-EXTEND is Dr. Musialek's clinical evaluation of CGuard™ procedures in 101 consecutive all-comer patients, building upon the earlier PARADIGM study. For more information about InspireMD and its offerings, visit www.inspiremd.com. About PARADIGM PARADIGM is an investigator-initiated Prospective evaluation of All-comer peRcutaneous cArotiD revascularization In symptomatic and increased-risk asymptomatic carotid artery stenosis, using CGuard™ Mesh-covered embolic prevention stent system. At EuroPCR 2015, Dr. Musialek summarized the results of his PARADIGM evaluation of 71 CGuard™ procedures in unselected all-comer patients: 1) stent system success and procedure success rate of 100%; 2) periprocedural complications of 0%, and remained at 0% at 30 days; and 3) no MACNE occurred periprocedurally or at 30 days, by operator-independent neurologist and non-invasive cardiologist evaluation. About InspireMD, Inc. InspireMD seeks to utilize its proprietary MGuard™ with MicroNet™ technology to make its products the industry standard for embolic protection and to provide a superior solution to the key clinical issues of current stenting in patients with a high risk of distal embolization, no reflow and major adverse cardiac events. InspireMD intends to pursue applications of this MicroNet technology in coronary, carotid (CGuard™), neurovascular, and peripheral artery procedures. InspireMD's common stock is quoted on the NYSE MKT under the ticker symbol NSPR. Forward-looking Statements This press release contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.


Investor Contacts:

InspireMD, Inc.

Craig Shore

Chief Financial Officer

Phone: 1-888-776-6804 FREE

Email: [email protected]


PCG Advisory

Vivian Cervantes

Investor Relations

Phone: (212) 554-5482





Read more...

Ratios

vs
industry
vs
history
PB Ratio 0.25
NSPR's PB Ratio is ranked higher than
98% of the 298 Companies
in the Global Medical Devices industry.

( Industry Median: 3.11 vs. NSPR: 0.25 )
Ranked among companies with meaningful PB Ratio only.
NSPR' s PB Ratio Range Over the Past 10 Years
Min: 0.23  Med: 8.84 Max: 360.33
Current: 0.25
0.23
360.33
PS Ratio 0.21
NSPR's PS Ratio is ranked higher than
96% of the 296 Companies
in the Global Medical Devices industry.

( Industry Median: 3.20 vs. NSPR: 0.21 )
Ranked among companies with meaningful PS Ratio only.
NSPR' s PS Ratio Range Over the Past 10 Years
Min: 0.19  Med: 9.8 Max: 98.75
Current: 0.21
0.19
98.75
EV-to-EBIT -0.29
NSPR's EV-to-EBIT is ranked higher than
99% of the 275 Companies
in the Global Medical Devices industry.

( Industry Median: 24.54 vs. NSPR: -0.29 )
Ranked among companies with meaningful EV-to-EBIT only.
NSPR' s EV-to-EBIT Range Over the Past 10 Years
Min: -49.4  Med: -2.8 Max: 0.5
Current: -0.29
-49.4
0.5
EV-to-EBITDA -0.29
NSPR's EV-to-EBITDA is ranked higher than
99% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 19.31 vs. NSPR: -0.29 )
Ranked among companies with meaningful EV-to-EBITDA only.
NSPR' s EV-to-EBITDA Range Over the Past 10 Years
Min: -50  Med: -2.8 Max: 0.5
Current: -0.29
-50
0.5
Current Ratio 1.80
NSPR's Current Ratio is ranked lower than
68% of the 321 Companies
in the Global Medical Devices industry.

( Industry Median: 2.38 vs. NSPR: 1.80 )
Ranked among companies with meaningful Current Ratio only.
NSPR' s Current Ratio Range Over the Past 10 Years
Min: 0.68  Med: 1.67 Max: 4.68
Current: 1.8
0.68
4.68
Quick Ratio 1.69
NSPR's Quick Ratio is ranked lower than
52% of the 321 Companies
in the Global Medical Devices industry.

( Industry Median: 1.79 vs. NSPR: 1.69 )
Ranked among companies with meaningful Quick Ratio only.
NSPR' s Quick Ratio Range Over the Past 10 Years
Min: 0.57  Med: 1.67 Max: 4.28
Current: 1.69
0.57
4.28
Days Inventory 102.55
NSPR's Days Inventory is ranked higher than
65% of the 289 Companies
in the Global Medical Devices industry.

( Industry Median: 130.04 vs. NSPR: 102.55 )
Ranked among companies with meaningful Days Inventory only.
NSPR' s Days Inventory Range Over the Past 10 Years
Min: 102.55  Med: 135.33 Max: 315.56
Current: 102.55
102.55
315.56
Days Sales Outstanding 68.61
NSPR's Days Sales Outstanding is ranked higher than
50% of the 272 Companies
in the Global Medical Devices industry.

( Industry Median: 68.94 vs. NSPR: 68.61 )
Ranked among companies with meaningful Days Sales Outstanding only.
NSPR' s Days Sales Outstanding Range Over the Past 10 Years
Min: 63.99  Med: 82.25 Max: 138.85
Current: 68.61
63.99
138.85
Days Payable 125.95
NSPR's Days Payable is ranked higher than
78% of the 259 Companies
in the Global Medical Devices industry.

( Industry Median: 59.71 vs. NSPR: 125.95 )
Ranked among companies with meaningful Days Payable only.
NSPR' s Days Payable Range Over the Past 10 Years
Min: 71.71  Med: 112.28 Max: 132.86
Current: 125.95
71.71
132.86

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -119.50
NSPR's 3-Year Average Share Buyback Ratio is ranked lower than
96% of the 218 Companies
in the Global Medical Devices industry.

( Industry Median: -3.90 vs. NSPR: -119.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
NSPR' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -141  Med: -106.1 Max: -34.4
Current: -119.5
-141
-34.4

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 0.46
NSPR's Price-to-Net-Cash is ranked higher than
98% of the 103 Companies
in the Global Medical Devices industry.

( Industry Median: 17.13 vs. NSPR: 0.46 )
Ranked among companies with meaningful Price-to-Net-Cash only.
NSPR' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.43  Med: 7.6 Max: 110.32
Current: 0.46
0.43
110.32
Price-to-Net-Current-Asset-Value 0.30
NSPR's Price-to-Net-Current-Asset-Value is ranked higher than
99% of the 206 Companies
in the Global Medical Devices industry.

( Industry Median: 6.88 vs. NSPR: 0.30 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
NSPR' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.29  Med: 5.42 Max: 24.94
Current: 0.3
0.29
24.94
Price-to-Tangible-Book 0.24
NSPR's Price-to-Tangible-Book is ranked higher than
98% of the 263 Companies
in the Global Medical Devices industry.

( Industry Median: 4.11 vs. NSPR: 0.24 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
NSPR' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.23  Med: 4.8 Max: 22.59
Current: 0.24
0.23
22.59
Price-to-Median-PS-Value 0.02
NSPR's Price-to-Median-PS-Value is ranked higher than
99% of the 242 Companies
in the Global Medical Devices industry.

( Industry Median: 1.03 vs. NSPR: 0.02 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
NSPR' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.02  Med: 0.92 Max: 2.79
Current: 0.02
0.02
2.79
Earnings Yield (Greenblatt) % -355.69
NSPR's Earnings Yield (Greenblatt) % is ranked higher than
99% of the 432 Companies
in the Global Medical Devices industry.

( Industry Median: 2.17 vs. NSPR: -355.69 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
NSPR' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -422.83  Med: 497.2 Max: 2327
Current: -355.69
-422.83
2327

More Statistics

Revenue (TTM) (Mil) $1.89
EPS (TTM) $ -13.17
Beta1.29
Short Percentage of Float22.96%
52-Week Range $0.60 - 13.75
Shares Outstanding (Mil)1.47

Analyst Estimate

Dec17
Revenue (Mil $)
EPS ($) -0.37
EPS without NRI ($) -0.37
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for NSPR

Headlines

Articles On GuruFocus.com
InspireMD Announces Pricing of Public Offering of Approximately $14.6 Million Jun 30 2016 
CORRECTION - InspireMD Announces Pricing of Public Offering of Approximately $14.6 Million Jun 30 2016 
InspireMD Announces Amendment to Loan & Security Agreement With Hercules Capital Jun 14 2016 
InspireMD Names Dr. James Barry as President and CEO Jun 07 2016 
InspireMD Announces Late-Breaking Trial Presentation on CGuard(TM) Embolic Prevention System at Euro May 05 2016 
UPDATE: InspireMD Receives Audit Opinion With Going Concern Explanation Mar 31 2016 
Insiders Roundup: Sales on Facebook Mar 25 2016 
InspireMD Announces Closing of Public Offering Mar 21 2016 
InspireMD Announces Closing of Private Placement to Certain Officers and Directors Mar 21 2016 
InspireMD Announces Pricing of Public Offering Mar 16 2016 

More From Other Websites
InspireMD Announces Distribution Agreement for CGuard(TM) EPS in the Netherlands Apr 06 2017
InspireMD Announces Listing of Series B Warrants on the NYSE MKT Apr 05 2017
InspireMD Announces Distribution Agreement for CGuardTM in Turkey Apr 04 2017
InspireMD Announces Commercial Launch of CGuard(TM) EPS in the Russian Federation at the ICCA Stroke... Mar 30 2017
InspireMD Repays Term Note Ahead of Schedule Mar 22 2017
InspireMD, Inc. :NSPR-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017 Mar 21 2017
InspireMD Announces Distribution Agreement for CGuard(TM) EPS in Hong Kong Mar 21 2017
InspireMD Announces CGuard Distribution Agreement for the Russian Federation Mar 20 2017
InspireMD Reports Continued Progress in the Transition of European Sales and Distribution Mar 15 2017
Dawson James Securities Announces the Completion of Public Offering with InspireMD Inc. for Gross... Mar 15 2017
InspireMD Announces Closing of Public Offering of Approximately $6.8 Million Mar 14 2017
InspireMD, Inc. :NSPR-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017 Mar 14 2017
InspireMD Announces Pricing of Public Offering of up to $7.5 Million Mar 09 2017
InspireMD Provides Year End Business Update; Reports Financial Results for the Fourth Quarter and... Feb 17 2017
InspireMD Provides Year End Business Update and Reports Financial Results for the Fourth Quarter and... Feb 16 2017
InspireMD's CGuard(TM) Carotid Embolic Prevention System to be Featured at LINC 2017 Jan 24 2017
InspireMD Announces Change in Presentation Time at LD Micro Main Event Conference to Tuesday,... Dec 05 2016
InspireMD to Present at LD Micro Main Event on December 6 Nov 28 2016
InspireMD Reports Financial Results for the Third Quarter Ended September 30, 2016 Nov 14 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)